Share on StockTwits

Stemline Therapeutics (NASDAQ:STML) COO Kenneth Hoberman bought 2,000 shares of the stock on the open market in a transaction that occurred on Tuesday, September 2nd. The stock was purchased at an average cost of $10.99 per share, for a total transaction of $21,980.00. Following the completion of the purchase, the chief operating officer now directly owns 89,535 shares of the company’s stock, valued at approximately $983,990. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Stemline Therapeutics (NASDAQ:STML) traded down 0.27% during mid-day trading on Wednesday, hitting $10.92. The stock had a trading volume of 143,712 shares. Stemline Therapeutics has a 1-year low of $10.509 and a 1-year high of $47.25. The stock’s 50-day moving average is $11.66 and its 200-day moving average is $16.40. The company’s market cap is $141.4 million.

Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.24. On average, analysts predict that Stemline Therapeutics will post $-2.39 earnings per share for the current fiscal year.

Stemline Therapeutics, Inc (NASDAQ:STML) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk.

Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.